Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1835-1843

  Smith, David C ^a   Dunn, Rodney L ^a   Strawderman, Myla S ^a   Pienta, Kenneth J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYTOTOXIC AGENT; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE SODIUM; ETOPOSIDE; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STATISTICAL MODEL;

EID: 0031832733     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1835     Document Type: Article

References (37)

1. Eisenberger MA, Sinibaldi VJ, Reyno LM,et al.:Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer, J Clin Oncol 13:2174-2186, 1995
2. Pienta KJ, Redman B, Hussain MC,et al.:Phase evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994
3. Hudes OR, Greenberg R, Krigel RL,et al.:Phase study of estramustine and vinblastine, two microtubule inhibitors, in hormonerefractory prostate cancer. J Clin Oncol 10:1754-1761, 1992
4. Schmidt 3D, Scott WW, Gibbons R,et al.:Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer 45:1937-1946, 1980
5. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013-1021, 1985
6. Eisenberger MA, Simon R, O'Dwyer PJ: A réévaluation of nonhormonal cytotoxic chemotherapy in treatment of prostatic carcinoma. J Clin Oncol 3:827-841, 1985
7. Scher HI, Curley T, Geller N,et al.:Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8:1830-1838, 1996
8. Wang MC, Valenzuela CA, Murphy GP: Purification of a human prostate specific antigen. Invest Urol 17:159-163, 1979
9. Lilja H: A kallikrein-like serine protease in prostate fluid cleaves the predominant seminal vesicle protein. J Clin Invest 79:1899-1903, 1985
10. Chybowski FM, Keller JJ, Bergstralh EJ: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate-specific antigen is superior to all other clinical parameters. JUrol 145:313-318, 1991
11. Oesterling JE, Chan DW, Epstein JI: Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139:766-772, 1988
12. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate-specific antigen in patients with prostate cancer. J Urol 142:1011-1017, 1989
13. Zagars GK, von Eschenbach AC: Prostate-specific antigen. An important marker for prostate cancer treated by external-beam radiation therapy. Cancer 72:538-548, 1993
14. Matzkin H, Soloway MS: Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma. Urology 40:78-80, 1992
15. Matzkin H, Eber P, Todd B,et al.:Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 70:2302-2309, 1992
16. Miller JI, Ahmann FR, Drach GW,et al.:The clinical usefulness of serum prostate-specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147:956-961, 1992
17. Zietman AL, Dallow KC, McManus PA,et al.:Time to second prostate-specific antigen failure is a surrogate end point for prostate cancer death in a prospective trial of therapy for localized disease. Urology 47:236-239, 1996
18. Ferro MA, Gillatt D, Symes MO,et al.:High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology 34:134-138, 1989
19. Fossa SD, Hosbach G, Paus E: Flutamide in hormone-resistant prostatic cancer. J Urol 144:1411-1414, 1990
20. Seidman AD, Scher HI, Petrylak D,et al.:Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostate cancer. J Urol 147:931-934, 1992
21. Kelly WK, Scher H, Mazumdar M,et al.:Prostate-specific antigen as a measure of disease outcome in metastatic hormonerefractory prostate cancer. J Clin Oncol 41:190-191, 1989
22. Sridhara R, Eisenberger MA, Sinibaldi VJ,et al.:Evaluation of prostate-specific antigen as a surrogate marker for response of hormonerefractory prostate cancer to suramin therapy. J Clin Oncol 3:2944-2953, 1996
23. Seidman AD, Scher HI, Petrylak D,et al.:Estramustine and vinblastine: Use of prostate-specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 147:931-934, 1992
24. Pienta KJ, Redman BG, Bandekar R,et al.:A phase trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer. Urology 50:401-406, 1997
25. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1989
26. Reyno LM, Egorin MJ, Eisenberger MA,et al.:Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187-2195, 1995
27. Kobayashi K, Yokes EE, Ratain MJ,et al.:Survival (surv) of prostate cancer (PrCA) patients (pts) treated with suramin (SUR) by intermittent infusion without adaptive control: Possible negative impact of prior flutamide (flut) therapy (rx) on survival. Proc Amer Soc Clin Oncol 15:481, 1996 (abstr)
28. Hosang M: Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 29:265-273, 1985
29. Coffey RJ Jr, Leof EB, Shipley GD,et al.:Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 132:143-148, 1987
30. Pienta KJ, Isaacs WB, Vindivich D,et al.:The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 145:199-202, 1991
31. Rago R, Mitchen J, Cheng AL,et al.:Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. Cancer Res 51:6629-6635, 1991
32. Thallman GA, Sikes RA, Chang S,et al.:Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 88:794-801, 1996
33. Eisenberger MA, Nelson WG: How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of cautionl J Natl Cancer Inst 88:779-781, 1996
34. Stein BS, Vangore S, Petersen RO,et al.:Immunoperoxidase localization of prostate-specific antigen. Am J Surg Pathol 6:553-557, 1982
35. Ford TF, Butcher DN, Masters JR,et al.:Immunocytochemical localization of prostate-specific antigen: Specificity and application to clinical practice. Br J Urol 57:50-55, 1985
36. Partin AW, Carter HB, Chan DW,et al.:Prostate-specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143:747-752, 1990
37. Smith DC, Tucker JA, Trump D: Hypercalcemia and neuroendocrine carcinoma of the prostate: A report of three cases and a review of the literature. J Clin Oncol 10:499-505, 1992